Mangalam Drugs And Organics Ltd Share Price Today

Sunil Kotak

22 Sep • 9:47 AM · SEBI-Registered Analyst

Berger Paints steps up defence in competition with others

Berger Paints steps up defence as Birla Opus, JSW Dulux intensify paint market battle

BERGEPAINT

SEBI RA – Shubh Consultancy – Sunil Kotak – INH000015826 Berger Paints India Ltd., controlled by the billionaire Dhingra family, is fortifying its business as India’s second-largest paintmaker seeks to fend off a challenge from deep-pocketed tycoons in the $8.2 billion sector. The Kolkata-based company, with a nearly 20% revenue share among publicly listed peers, has identified two areas for what its Chief Executive Officer Abhijit Roy called an “insurgent act.” Berger is strengthening teams in its weaker markets of Mumbai and Pune in the west, and Chennai and Bengaluru in the south, Roy said in an interview. The firm also plans to launch a new line of luxury paints, and add as many as 250 mostly exclusive outlets every year to take the count to 2,500 by March 2029. New rivals intensify pricing pressure The company’s on the back foot after billionaires Kumar Mangalam Birla and Sajjan Jindal unleashed a pricing war to wrest business from it and sector leader Asian Paints Ltd., which controls over 50% market share. Birla Opus and Jindal’s JSW Dulux Ltd. are gaining ground, said brokerage PL Capital in a Sept 16 note. Berger’s shares are down about 16% this year compared to a 10% fall the nation’s benchmark measure. The firm, valued at 525.4 billion rupees ($5.5 billion), is 64.56% owned by UK Paints India Pvt., which is controlled by Kuldip Singh Dhingra and his brother Gurbachan Singh Dhingra. The siblings acquired the business in 1991 from former liquor tycoon Vijay Mallya, whose Kingfisher Airlines Ltd. folded in 2012 after failing to pay creditors. All this is for information This is not a buy/sell recommendation. Thank you, Technofunda24

Pyrifera Investment Advisors

15 Sep • 10:35 PM · SEBI-Registered Analyst

Mangalam Drugs Faces Prolonged ₹15.57 Crore Default

Mangalam Drugs and Organics Limited continues to grapple with severe liquidity constraints, reporting ongoing defaults on its revolving working capital facilities totaling ₹15.57 crore as of mid-July 2026. Key Highlights: Default Details: The overdue amount includes ₹9.51 crore to Bank of Maharashtra and ₹6.06 crore to Bank of Baroda. The default has persisted for nearly 11 months (since October 2025), with balances continuously exceeding sanctioned drawing power. Q1 FY27 Financials: The company showed marginal operational improvement, narrowing its standalone net loss by ~45% YoY to ₹7.55 crore (from ₹13.73 crore). However, operating revenue remained stagnant at ₹57.12 crore. Strategic Risks & Market Implications: Credit & NPA Threat: The prolonged duration of the default places the company’s credit rating under severe pressure and significantly increases the risk of lenders classifying the accounts as Non-Performing Assets (NPAs) or initiating recovery actions. Operational Bottleneck: This persistent working capital gap restricts access to fresh credit, which could eventually disrupt raw material procurement and hamper production volumes at the company’s critical Vapi API manufacturing facility. Outlook: While management has made progress in cost control and inventory management to narrow losses, the systemic liquidity crisis remains unresolved. An urgent debt restructuring package or fresh equity infusion is critical to restore banking relationships, normalize working capital cycles, and safeguard ongoing manufacturing operations.

MANGALAM

Sarathi Research

12 Sep • 9:08 AM · SEBI-Registered Analyst

Vodafone Idea Gets Reported $3.5 Billion Debt Backing

!IDEA Vodafone Idea is reportedly set to receive around $3.5 billion in debt financing from a consortium of lenders led by State Bank of India, according to people familiar with the matter. Union Bank of India and the National Bank for Financing Infrastructure and Development are also understood to be part of the lending group. The proposed financing is expected to support Vodafone Idea’s network expansion and improvement as the telecom operator works to strengthen its position against Bharti Airtel and Reliance Jio. The reported loan could have a tenure of nearly 10 years, with conditions including Kumar Mangalam Birla remaining chairman throughout the loan period and repayment guarantees in case of default. Vodafone Idea and the lenders had not officially confirmed the arrangement when the report emerged. The development comes as the company continues efforts to strengthen its financial position and invest in its network infrastructure. Disclaimer: The views expressed purely for educational and informational purposes and do not constitute financial advice or a recommendation to buy, sell, or hold any security

Sunil Kotak

4 Sep • 7:55 AM · SEBI-Registered Analyst

Aditya Birla Group launches wires, cables business

Aditya Birla Group launches wires, cables business with ₹1,800 crore bet Stock on radar

ULTRACEMCO

SEBI RA – Shubh Consultancy – Sunil Kotak – INH000015826 The Aditya Birla group on Thursday announced the launch of its wires and cables business Ultravolt. Backed by an investment of ₹1,800 crore, Ultravolt will be the second-largest player in the wires segment by capacity, the group said. Housed under UltraTech Cement, the group’s flagship firm, Ultravolt aims to build a scaled national brand and become one of the top two players within five years. UltraTech’s entry into the wires and cables market extends its participation in the construction value chain beyond grey cement, ready-mix concrete, building products, and white cement in line with its stated building solutions strategy. It also enables UltraTech to participate more deeply in the growing opportunity around homebuilding, infrastructure, and electrification, the group noted. Kumar Mangalam Birla, chairman of the $72 billion Aditya Birla group, said: “Wires and cables are becoming central to India's next phase of development. They sit at the intersection of three mega trends in the Indian economy — urbanisation, electrification, and digitisation. More than 100 million new homes over the next decade, expanding energy infrastructure, and the rapid rise of data centres are poised to fuel a boom in the category. Our distinctive advantage comes from a deep understanding of the product, its underlying components, and the adjacent ecosystems.” All this is for information This is not a buy/sell recommendation. Thank you, Technofunda24

Adarsh Nimborkar (SEBI IA)

20 Aug • 12:56 PM · SEBI-Registered Analyst

Mangalam Cement Ltd – Company Analysis

MANGLMCEM

Mangalam Cement Ltd is a Birla Group cement manufacturer operating primarily across North and Central India under the Birla Uttam brand. The company manufactures and markets grey cement and benefits from India's long-term infrastructure, housing and construction demand. FY26 showed a substantial improvement in profitability. Revenue from operations increased to approximately ₹1,758 crore from ₹1,681 crore, while EBITDA rose 19.6% to ₹261 crore. Profit before exceptional items and tax increased sharply from ₹70 crore to ₹116 crore, and reported net profit reached ₹129 crore compared with ₹45 crore in FY25. However, the headline profit growth needs some caution because FY26 benefited from a significant tax credit, while an exceptional expense of about ₹21.8 crore was also recorded. Q4 FY26 revenue was around ₹507 crore and reported profit ₹65 crore, but Groww notes that the quarterly profit was boosted by a tax reversal, so underlying operating earnings are more important than the headline PAT number. Looking ahead, Mangalam Cement can benefit from higher cement demand, capacity expansion and improving utilization of its enlarged Aligarh facility. The company's preferred-bidder status for a limestone mining block in Rajasthan could also strengthen long-term raw-material security and potentially improve vertical integration. However, cement remains a cyclical and highly competitive industry, with profitability sensitive to cement prices, fuel costs, freight expenses and capacity utilization. The company also carries meaningful leverage, with debt-to-equity around 0.91. At roughly ₹941 per share and a P/E near 20, the stock is not extremely cheap despite trading below the industry's reported P/E. Overall, Mangalam Cement has improving fundamentals and a credible capacity-led growth story, but investors should focus on normalized earnings and debt reduction rather than the unusually high FY26 profit growth.

Prameela Balakkala

9 Aug • 6:27 PM · SEBI-Registered Analyst

Mangalam Cement Q1: Profit Falls, Margins Under Pressure

MANGLMCEM

📌 Mangalam Cement Q1 FY26 Results Net Profit: ₹181M vs ₹322M (YoY) ⬇️, showing a sharp decline in earnings despite steady sales. Revenue: ₹4.5B vs ₹4.5B (YoY) ➖, reflecting flat topline growth in a competitive market. EBITDA: ₹534M vs ₹752M (YoY) ⬇️, highlighting weaker operating performance. EBITDA Margin: 11.72% vs 16.6% (YoY) ⬇️, underscoring cost pressures. 📊 Fundamentals & Ratios Revenue: ~₹18B annually, steady but limited growth. Net Profit: ~₹1.1B, modest profitability. Debt-to-Equity: ~0.5, moderate leverage. P/E Ratio: ~14–16, fair valuation vs peers. ROE: ~10–11%, average capital efficiency. Dividend Yield: ~1.0%, consistent payouts. 🏦 Projects Capacity expansion initiatives to capture demand. Green cement & sustainability-focused manufacturing. Strengthening distribution network in key regions. Efficiency improvements in plant operations. ⚠️ Risks Rising input costs pressuring margins. Flat revenue growth despite demand. Competitive intensity from larger players. Regulatory compliance challenges. Execution risks in expansion projects.

Mangalam Drugs And Organics Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Mangalam Drugs And Organics Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Mangalam Drugs And Organics Ltd.?

What is the market cap of Mangalam Drugs And Organics Ltd.?

Should I buy Mangalam Drugs And Organics Ltd. stock now?

What is the 52 week high and low of Mangalam Drugs And Organics Ltd.?

Is the Mangalam Drugs And Organics Ltd. stock good to buy?

Is Mangalam Drugs And Organics Ltd. a good buy for the long term?

Is Mangalam Drugs And Organics Ltd. overvalued or undervalued?

What is the PE and PB ratio of Mangalam Drugs And Organics Ltd.?